logo Hematology/Oncology Research Studies: Open for Enrollment Date: 05/27/20


Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors

NCT#/Phase: NCT02867592
Phase 2
IRB#: 2017-087
Description: This open label two-stage singla arm study tests to determine the objective response rate (complete response + partial response) of XL184 in children and young adults with Ewing Sarcoma, Rhabdomyosarcoma, Non rhabdomyosarcoma soft tissue sarcomas, Wilms tumor, and Rare tumors. Patients will receive XL184 aministered at 40 mg/m2/day on a continuous dosing schedule (one cycle=28 days).
Inclusion: Individuals must be between 2 and 30 years of age at the time of study entry for all strata except upper age limit of <= 18 years of age for MTC, RCC, HCC and must have a BSA >= 0.35m2. Patients must have recurrent or refractory disease, or newly diagnosed disease with no none curative therapy or therapy proven to prolong survival with an acceptable quality of life and have histologic verification of one of the following malignancies: Ewing sarcoma, Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma soft tissue sarcoma (STS), Wilm's Tumor, or Rare Tumor.
Enrollment Status: Open for enrollment
Sponsor: Children's Oncology Group (COG)
Principal Investigator(s): Carla Golden, MD
Contact(s): Diane Olszewski (510-428-3885 x 3246)
COG CRA Office (510-428-3885 x8334)
Study Link: https://clinicaltrials.gov/ct2/show/NCT02867592

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 &bull Phone: (510) 428-3000